B of A Securities Maintains Neutral on Y-mAbs Therapeutics, Lowers Price Target to $12

Benzinga · 03/05/2025 18:08
B of A Securities analyst Alec Stranahan maintains Y-mAbs Therapeutics (NASDAQ:YMAB) with a Neutral and lowers the price target from $14 to $12.